Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMZA5PQ)

Drug Name
Glipizide Drug Info
Synonyms
Aldiab; Digrin; Dipazide; Glibenese; Glibetin; Glican; Glide; Glidiab; Glidiazinamide; Glipid; Glipizida; Glipizidum; Glucolip; Glucotrol; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; Glypidizine; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; Napizide; Ozidia; Semiglynase; Sucrazide; Alphapharm Brand of Glipizide; Glibenese Brand of Glipizide; Glipizide Kenfarma Brand; Glucotrol XL; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; CP 28720; K 4024; K4024; PfizerBrand 1 of Glipizide; Pfizer Brand 2 of Glipizide; TK 1320; CP 28,720; CP-28720; G-117; Glipizida [INN-Spanish]; Glipizide Extended-Release Tablets; Glipizidum [INN-Latin]; Gluco-Rite; Glucotrol (TN); K-4024; KS-1068; Samarium(III) ionophore I; Glipizide (USP/INN); Glipizide [USAN:BAN:INN]; Glucotrol XL, Glucotrol, Glipizide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; 1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea
Therapeutic ClassHypoglycemic Agents
Cross-matching ID
PubChem CID
3478
ChEBI ID
CHEMBL1073
CAS Number
CAS 29094-61-9
TTD Drug ID
D0Z4SB
VARIDT Drug ID
DR00329
INTEDE Drug ID
DR0778
ACDINA Drug ID
D00303

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mismatch repair 2.39 0.00e+0 22/23 (95.65%) RPA3;RFC2;SSBP1;...
Proteasome 2.27 0.00e+0 44/46 (95.65%) PSMA7;PSMA2;PSMB6;...
DNA replication 2.25 0.00e+0 34/36 (94.44%) POLE2;RPA3;RFC2;...
Parkinson disease 2.02 0.00e+0 176/249 (70.68%) PSMA7;PSMA2;PSMB6;...
Pantothenate and CoA biosynthesis 1.99 1.24e-3 14/21 (66.67%) ALDH2;ENPP1;BCAT1;...
Ribosome biogenesis in eukaryotes 1.88 2.06e-3 52/108 (48.15%) RAN;NHP2;RPP40;...
RNA transport 1.88 1.77e-3 128/186 (68.82%) SUMO3;RAN;GEMIN2;...
Spliceosome 1.86 1.55e-3 101/150 (67.33%) SNRPE;LSM5;SNRPG;...
Nucleotide excision repair 1.85 1.38e-3 40/47 (85.11%) POLE2;GTF2H5;RPA3;...
Fatty acid elongation 1.82 3.71e-3 19/27 (70.37%) ELOVL2;PPT1;ACAA2;...
Oxidative phosphorylation 1.78 7.88e-3 93/133 (69.92%) ATP6V1D;NDUFA9;NDUFA4;...
Base excision repair 1.76 8.77e-3 29/33 (87.88%) POLE2;APEX1;POLB;...
Amyotrophic lateral sclerosis 1.71 1.38e-2 267/364 (73.35%) PSMA7;PSMA2;PSMB6;...
Ribosome 1.68 1.86e-2 113/158 (71.52%) MRPL15;MRPL20;MRPL22;...
Thiamine metabolism 1.65 2.43e-2 12/15 (80%) AK4;ALPL;AK2;...
Basal transcription factors 1.63 3.33e-2 37/45 (82.22%) GTF2H5;GTF2E1;TBP;...
Huntington disease 1.61 3.68e-2 233/306 (76.14%) PSMA7;PSMA2;PSMB6;...
Cysteine and methionine metabolism 1.59 3.92e-2 43/50 (86%) PSAT1;SRM;BCAT1;...
Viral protein interaction with cytokine and cytokine re... -1.64 4.71e-2 84/100 (84%) IL10RA;LTBR;IL6R;...
Osteoclast differentiation -1.66 4.22e-2 117/127 (92.13%) MAP2K1;SIRPA;MAP2K7;...
Insulin resistance -1.67 4.18e-2 96/108 (88.89%) NR1H3;INSR;PIK3CA;...
Kaposi sarcoma-associated herpesvirus infection -1.67 4.36e-2 172/193 (89.12%) HLA-F;CREBBP;MAP2K1;...
C-type lectin receptor signaling pathway -1.68 4.08e-2 93/104 (89.42%) CD209;PRKCD;MALT1;...
Thyroid cancer -1.69 4.15e-2 36/37 (97.3%) MAPK3;BAX;RXRB;...
Type II diabetes mellitus -1.70 3.84e-2 42/46 (91.3%) MAPK3;PKM;SOCS1;...
MicroRNAs in cancer -1.73 3.22e-2 146/310 (47.1%) TIMP3;MAPK3;SOCS1;...
Aldosterone-regulated sodium reabsorption -1.74 3.04e-2 34/37 (91.89%) PDPK1;SCNN1B;MAPK3;...
IL-17 signaling pathway -1.74 3.22e-2 84/94 (89.36%) HSP90B1;MAPK3;TRAF5;...
Chemokine signaling pathway -1.75 3.09e-2 163/192 (84.9%) ROCK1;GRK2;ELMO1;...
Pancreatic cancer -1.76 3.12e-2 75/76 (98.68%) PLD1;MAPK3;BAX;...
NOD-like receptor signaling pathway -1.77 2.51e-2 145/181 (80.11%) TP53BP1;TRAF3;IL18;...
Choline metabolism in cancer -1.79 2.20e-2 84/98 (85.71%) PLD1;DGKD;MAPK3;...
ABC transporters -1.79 2.39e-2 37/45 (82.22%) TAP2;ABCC8;ABCC1;...
Phospholipase D signaling pathway -1.81 2.13e-2 134/148 (90.54%) MS4A2;PLD1;ADCY3;...
Thyroid hormone signaling pathway -1.81 2.34e-2 112/121 (92.56%) MAPK3;SLC9A1;THRA;...
Renin-angiotensin system -1.83 2.03e-2 20/23 (86.96%) AGTR2;ATP6AP2;ACE2;...
Rheumatoid arthritis -1.84 1.79e-2 78/93 (83.87%) JUN;TEK;MMP3;...
Small cell lung cancer -1.85 2.05e-2 90/92 (97.83%) LAMB1;BAX;TRAF5;...
NF-kappa B signaling pathway -1.85 2.17e-2 90/104 (86.54%) EDAR;IRAK4;PLAU;...
Notch signaling pathway -1.86 2.60e-2 49/59 (83.05%) DVL2;NUMB;TLE3;...
Lysosome -1.88 1.30e-2 115/128 (89.84%) MAN2B1;AP1G2;PLA2G15;...
AGE-RAGE signaling pathway in diabetic complications -1.93 8.68e-3 97/100 (97%) COL4A3;JAK2;SERPINE1;...
Other glycan degradation -1.93 1.30e-2 13/18 (72.22%) MAN2B1;MAN2B2;MANBA;...
TNF signaling pathway -2.02 1.30e-2 103/112 (91.96%) MAPK3;VEGFD;MMP14;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 3.33uM - 10uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 12uM 6H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 3.33uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 3.33uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 3.33uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 3.33uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 3.33uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 3.33uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 3.33uM - 10uM 24H